347396-82-1

GPTKB entity

Statements (28)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkbp:approvedBy gptkb:FDA
gptkbp:ATCCode N05CM25
gptkbp:CASNumber gptkb:347396-82-1
gptkbp:developedBy gptkb:Merck_&_Co.
gptkbp:hasMolecularFormula C23H23ClN6O2
gptkbp:hasSMILES CN1CCN(CC1)C(=O)C2=CC(=C(C=C2)C)N3N=CC=N3
gptkbp:hasUNII 7XUQ444B8W
https://www.w3.org/2000/01/rdf-schema#label 347396-82-1
gptkbp:IUPACName [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
gptkbp:KEGGID gptkb:D10366
gptkbp:legalStatus prescription only
gptkbp:marketedAs gptkb:Belsomra
gptkbp:mechanismOfAction orexin receptor antagonist
gptkbp:molecularWeight 450.92 g/mol
gptkbp:name gptkb:Suvorexant
gptkbp:pregnancyCategory C (US)
gptkbp:PubChem_CID gptkb:CHEMBL2105757
DB09025
29341913
46215917
gptkbp:routeOfAdministration oral
gptkbp:sideEffect dizziness
headache
somnolence
gptkbp:usedFor treatment of insomnia
gptkbp:bfsParent gptkb:Lucentis
gptkbp:bfsLayer 5